SciELO - Scientific Electronic Library Online

 
vol.15 número2Caracterización de las inmunoglobulinas del ñandú (Rhea americana)Seroprevalencia y estudio de factores asociados a la neosporosis canina en animales ingresados al Hospital Escuela, FCV-UBA, Argentina índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Journal

Artigo

Indicadores

  • Não possue artigos citadosCitado por SciELO

Links relacionados

Compartilhar


InVet

versão On-line ISSN 1668-3498

Resumo

GOMEZ, N et al. Efficacy of a combination of two nucleoside and one non-nucleoside reverse transcriptase inhibitors in Feline Immunodeficiency Virus-naturally infected cats, during the last stages of the disease. InVet [online]. 2013, vol.15, n.2, pp.103-115. ISSN 1668-3498.

The aim of this study was to report the comparative results using combined antiviral drugs on naturally-infected FIV cats in the asymptomatic and AIDS stages of the disease. The drug combinations evaluated were zidovudine (ZDV) alone and ZDV + lamivudine (3TC) +Nevirapine. Plasma viral load was measured at the beginning of treatment and at one year. Total leucocytes, neutrophils and lymphocyte counts, CD4+/CD8+ ratios and biochemical profile values were also analyzed. Neurological disease was evaluated by evoked potentials determinations. The results showed a better efficacy of the combined therapy vs. ZDV alone, reducing the viral load, increasing the CD4+/CD8+ ratio and improving the clinical signs in the asymptomatic stage. In the AIDS stage the differences between both protocols were not so marked, but the combined therapy produced better results compared with ZDV alone. The auditory and visual evoked potentials put on evidence the neurological disease, even in cats without neurologic signs and were useful to evaluate the evolution of the patients with both protocols contrasted

Palavras-chave : FIV; Antiretrovirals; Asymptomatic stage; AIDS stage; Zidovudine; Lamivudine; Nevirapine.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )

 

Creative Commons License Todo o conteúdo deste periódico, exceto onde está identificado, está licenciado sob uma Licença Creative Commons